Iconovo AB (publ) (ICO.ST)
SEK 1.41
(7.25%)
SEK 1.41
(7.25%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -45.89 Million SEK | 8.78% |
| 2022 | -50.3 Million SEK | -92.31% |
| 2021 | -26.16 Million SEK | -52.68% |
| 2020 | -17.13 Million SEK | -55.68% |
| 2019 | -11 Million SEK | -156.28% |
| 2018 | -4.29 Million SEK | -395.56% |
| 2017 | 1.45 Million SEK | -40.96% |
| 2016 | 2.46 Million SEK | 374.24% |
| 2015 | -897.37 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -11.14 Million SEK | -16.01% |
| 2024 Q1 | -9.55 Million SEK | 3.56% |
| 2024 Q2 | -9.6 Million SEK | -0.6% |
| 2023 FY | -45.89 Million SEK | 8.78% |
| 2023 Q4 | -9.9 Million SEK | 0.68% |
| 2023 Q3 | -9.97 Million SEK | 23.63% |
| 2023 Q2 | -13.05 Million SEK | 1.05% |
| 2023 Q1 | -13.19 Million SEK | 29.77% |
| 2022 Q2 | -12.17 Million SEK | -34.47% |
| 2022 FY | -50.3 Million SEK | -92.31% |
| 2022 Q4 | -18.78 Million SEK | -86.94% |
| 2022 Q3 | -10.04 Million SEK | 17.46% |
| 2022 Q1 | -9.05 Million SEK | -4.62% |
| 2021 FY | -26.16 Million SEK | -52.68% |
| 2021 Q3 | -3.77 Million SEK | 43.18% |
| 2021 Q2 | -6.64 Million SEK | 6.06% |
| 2021 Q4 | -8.65 Million SEK | -129.08% |
| 2021 Q1 | -7.07 Million SEK | -56.75% |
| 2020 Q4 | -4.51 Million SEK | -128.64% |
| 2020 Q3 | -1.97 Million SEK | 69.14% |
| 2020 Q2 | -6.4 Million SEK | -50.84% |
| 2020 FY | -17.13 Million SEK | -55.68% |
| 2020 Q1 | -4.24 Million SEK | 43.65% |
| 2019 Q4 | -7.52 Million SEK | -325.85% |
| 2019 Q3 | -1.76 Million SEK | 31.58% |
| 2019 Q2 | -2.58 Million SEK | -626.27% |
| 2019 Q1 | 491 Thousand SEK | -69.05% |
| 2019 FY | -11 Million SEK | -156.28% |
| 2018 Q4 | 1.58 Million SEK | 176.49% |
| 2018 Q2 | 353 Thousand SEK | 108.49% |
| 2018 Q1 | -4.16 Million SEK | -189.0% |
| 2018 FY | -4.29 Million SEK | -395.56% |
| 2018 Q3 | -2.07 Million SEK | -687.54% |
| 2017 Q4 | 4.67 Million SEK | 260.62% |
| 2017 Q3 | -2.91 Million SEK | -349.36% |
| 2017 Q2 | 1.16 Million SEK | 179.01% |
| 2017 FY | 1.45 Million SEK | -40.96% |
| 2017 Q1 | -1.47 Million SEK | 0.0% |
| 2016 FY | 2.46 Million SEK | 374.24% |
| 2015 FY | -897.37 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 41.04% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 144.342% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 144.342% |
| Arcoma AB | 2.56 Million SEK | 1889.931% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 66.835% |
| BICO Group AB (publ) | -835.7 Million SEK | 94.508% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 283.744% |
| CellaVision AB (publ) | 130.3 Million SEK | 135.219% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 42.483% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -57.242% |
| C-Rad AB (publ) | 35.52 Million SEK | 229.173% |
| Duearity AB (publ) | -26.19 Million SEK | -75.234% |
| Dignitana AB (publ) | -17.36 Million SEK | -164.32% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 51.589% |
| Getinge AB (publ) | 2.41 Billion SEK | 101.903% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 32.487% |
| Integrum AB (publ) | 4.03 Million SEK | 1238.105% |
| Luxbright AB (publ) | -25.37 Million SEK | -80.861% |
| Mentice AB (publ) | -2.81 Million SEK | -1529.174% |
| OssDsign AB (publ) | -130.49 Million SEK | 64.83% |
| Paxman AB (publ) | 8.33 Million SEK | 650.946% |
| Promimic AB (publ) | -9.22 Million SEK | -397.656% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 71.308% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 17.435% |
| ScandiDos AB (publ) | -14.64 Million SEK | -213.333% |
| Sectra AB (publ) | 428.38 Million SEK | 110.713% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 23.012% |
| Senzime AB (publ) | -134.14 Million SEK | 65.789% |
| SpectraCure AB (publ) | -20.44 Million SEK | -124.519% |
| Stille AB | 26.64 Million SEK | 272.235% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 98.808% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 149.982% |